Key statistics
On Friday, Prelude Therapeutics Inc (PRLD:NSQ) closed at 2.23, 265.51% above the 52 week low of 0.6101 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.27 |
|---|---|
| High | 2.37 |
| Low | 2.18 |
| Bid | 2.00 |
| Offer | 2.50 |
| Previous close | 2.24 |
| Average volume | 268.92k |
|---|---|
| Shares outstanding | 62.87m |
| Free float | 57.90m |
| P/E (TTM) | -- |
| Market cap | 140.19m USD |
| EPS (TTM) | -1.47 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
- Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
- Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
- Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Prelude Therapeutics Announces Strategic Business Update
- Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
- Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
- Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
- Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
- Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
More ▼
